All In Biotech

Drug Trial Radar · NCT06888193

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

A Multicenter Open-label, Prospective Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Nov 5, 2025

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Mar 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.

Conditions

  • Moderate to Severe Plaque Psoriasis
  • Psoriatic Arthritis
  • Axial Spondyloarthritis
  • Hidradenitis Suppurativa

Interventions

  • BimekizumabDrug

    Bimekizumab under the care of their treating physician.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Concentration of bimekizumab in the breast milk on Day 1Time frame: Day 1
  2. Concentration of bimekizumab in the breast milk on Day 2Time frame: Day 2
  3. Concentration of bimekizumab in the breast milk on Day 3Time frame: Day 3
  4. Concentration of bimekizumab in the breast milk on Day 5Time frame: Day 5
  5. Concentration of bimekizumab in the breast milk on Day 7Time frame: Day 7
  6. Concentration of bimekizumab in the breast milk on Day 9Time frame: Day 9
  7. Concentration of bimekizumab in the breast milk on Day 11Time frame: Day 11
  8. Concentration of bimekizumab in the breast milk on Day 13Time frame: Day 13
  9. Concentration of bimekizumab in the breast milk on Day 15Time frame: Day 15
  10. Concentration of bimekizumab in the breast milk on Day 29Time frame: Day 29
  11. Concentration of bimekizumab in the breast milk on Day 57Time frame: Day 57

Locations

14 sites in 5 countries. Site status is shown where the registry gives one.

  • Up0122 105

    Santa Monica, California · Recruiting

  • Up0122 103

    South Miami, Florida · Recruiting

  • Up0122 104

    Boston, Massachusetts · Recruiting

  • Up0122 106

    Chapel Hill, North Carolina · Recruiting

  • Up0122 102

    Durham, North Carolina · Recruiting

  • Up0122 101

    Milwaukee, Wisconsin · Recruiting

  • Up0122 202

    Calgary, Canada · Recruiting

  • Up0122 201

    Vancouver, Canada · Recruiting

  • Up0122 301

    Freiburg im Breisgau, Germany · Recruiting

  • Up0122 303

    Herne, Germany · Recruiting

  • Up0122 501

    Barcelona, Spain · Recruiting

  • Up0122 502

    Barcelona, Spain · Recruiting

  • Up0122 602

    Lausanne, Switzerland · Recruiting

  • Up0122 601

    Sankt Gallen, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.